Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

被引：2

作者：

Parmar, Ambica ^{[1
,2
]}

Dai, Wei Fang ^{[2
]}

Dionne, Francois ^{[3
]}

Geirnaert, Marc ^{[4
]}

Denburg, Avram ^{[5
]}

Ahuja, Tarry ^{[6
]}

Beca, Jaclyn ^{[7
,8
]}

Bouchard, Sylvie ^{[9
]}

Chambers, Carole ^{[10
]}

Hunt, Melissa J. ^{[11
]}

Husereau, Don ^{[12
]}

Lungu, Elena ^{[13
]}

McDonald, Valerie

Mercer, Rebecca E. ^{[7
,8
]}

Mitera, Gunita ^{[14
]}

Munoz, Caroline ^{[7
]}

Naipaul, Rohini ^{[7
]}

Peacock, Stuart ^{[8
,15
]}

Potashnik, Tanya ^{[13
]}

Tadrous, Mina ^{[16
]}

Takhar, Pam ^{[7
]}

Taylor, Marianne ^{[17
]}

Trudeau, Maureen ^{[1
,2
]}

Wasney, Danica ^{[4
]}

Gavura, Scott ^{[7
]}

Chan, Kelvin K. W. ^{[1
,2
,8
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON M4N 3M3, Canada

[2] Univ Toronto, Temerty Fac Med, Toronto, ON M5S 1A8, Canada

[3] Prioritize Consulting Ltd, Vancouver, BC V6S 2B3, Canada

[4] CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada

[5] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada

[6] Canadian Agcy Drugs & Technol Hlth, Ottawa, ON K1S 5S8, Canada

[7] Ontario Hlth Canc Care Ontario, Toronto, ON M5G 2L3, Canada

[8] Canadian Ctr Appl Res Canc Control, Toronto, ON M5G 2L3, Canada

[9] Inst Natl Excellence Sante & Serv Sociaux INESSS, Quebec City, PQ G1V 4M3, Canada

[10] Alberta Hlth Serv, Calgary, AB T5J 3E4, Canada

[11] Hlth Canada, Ottawa, ON K1A 0K9, Canada

[12] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON K1G 5Z3, Canada

[13] Patented Med Prices Review Board, Ottawa, ON K1P 1C1, Canada

[14] Canadian Assoc Prov Canc Agcy, Toronto, ON M5H 1J8, Canada

[15] BC Canc Agcy, Vancouver, BC V5Z 1G1, Canada

[16] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada

[17] BC Canc, Kelowna, BC V1Y 5L3, Canada

来源：

CURRENT ONCOLOGY | 2023年 / 30卷 / 04期

基金：

加拿大健康研究院;

关键词：

oncology; decision-analysis; health technology assessment; multi-criteria decision analysis; HEALTH-CARE;

D O I：

10.3390/curroncol30040286

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration developed an MCDA rating tool to assess and prioritize potential post-market real-world evidence (RWE) questions/uncertainties emerging from public drug funding decisions in Canada. In collaboration with a group of multidisciplinary stakeholders from across Canada, the rating tool was developed following a three-step process: (1) selection of criteria to assess the importance and feasibility of an RWE question; (2) development of rating scales, application of weights and calculating aggregate scores; and (3) validation testing. An initial MCDA rating tool was developed, composed of seven criteria, divided into two groups. Group A criteria assess the importance of an RWE question by examining the (1) drug's perceived clinical benefit, (2) magnitude of uncertainty identified, and (3) relevance of the uncertainty to decision-makers. Group B criteria assess the feasibility of conducting an RWE analysis including the (1) feasibility of identifying a comparator, (2) ability to identify cases, (3) availability of comprehensive data, and (4) availability of necessary expertise and methodology. Future directions include partnering with the Canadian Agency for Drugs and Technology in Health's Provincial Advisory Group for further tool refinement and to gain insight into incorporating the tool into drug funding deliberations.

引用

页码：3776 / 3786

页数：11

共 50 条

[11] Informing real-world practice with real-world evidence: the value of PRECIS-2
Neta, Gila
Johnson, Karin E.
BMC MEDICINE, 2018, 16
[12] Informing real-world practice with real-world evidence: the value of PRECIS-2
Gila Neta
Karin E. Johnson
BMC Medicine, 16
[13] Real-world evidence enhances decision making
Malone, Daniel C.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1612 - 1614
[14] Real-world evidence use in assessments of cancer drugs by NICE
Bullement, Ash
Podkonjak, Tanja
Robinson, Mark J.
Benson, Eugene
Selby, Ross
Hatswell, Anthony J.
Shields, Gemma E.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (04) : 388 - 394
[15] Study Verifies Value of Real-World Evidence
Caruso, Catherine
CANCER DISCOVERY, 2019, 9 (07) : 819 - 819
[16] The Canadian Small Cell Lung Cancer Database (CASCaDe): A Multi-Institutional Real-World Evidence Collaboration
Moore, S.
Agulnik, J.
Bebb, G.
Dawe, D.
Elegbede, A.
Fung, A.
Ho, C.
Liu, G.
Lok, B.
Snow, S.
Wheatley-Price, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1189 - S1189
[17] ANALYSIS OF REAL-WORLD EVIDENCE AND REAL-WORLD DATA BY CONITEC, BRAZILIAN HTA AGENCY
Nita, M. E.
Riveros, B. S.
Vaz, P.
Mussolino, F.
VALUE IN HEALTH, 2016, 19 (03) : A286 - A286
[18] Utility of real-world evidence in biosimilar development
Arani, Ramin B.
Wang, Jessie
Pang, Dong
Sinha, Samriddhi Buxy
Uttenreuther-Fischer, Martina
Chow, Shein-Chung
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024,
[19] The Use of Real-world Data to Generate Real-world Evidence to Accelerate Neonatal Drug Development
Jackson, Shawn S.
Cravero, Joseph P.
Sun, Lena
Davis, Jonathan M.
JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, 2025, 37 (01) : 110 - 113
[20] Real-world evidence in the treatment of ovarian cancer
Eisenhauer, E. A.
ANNALS OF ONCOLOGY, 2017, 28 : 61 - 65

← 1 2 3 4 5 →